This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"A recent analysis suggests that ixazomib, an oral proteasome inhibitor (or PI), is tolerable and enhances therapeutic responses in patients with multiple myeloma. Ixazomib is approved for use in combination with lenalidomide and dexamethasone for patients who have already received 1 or more prior therapy. The promising results obtained for non-transplant patients taking ixazomib alone, if their disease has responded to primary induction therapy, point to a new possible treatment option for multiple myeloma. Multiple myeloma is a form of cancer that develops in bone marrow. Here, the body normally generates white blood cells that help fight off infection. But in multiple myeloma, malignant cells gradually crowd out these disease-fighting cells, compromising the body’s immune response, while also damaging the bones. The malignant cells also secrete large amounts of a non-functional protein which leads to kidney failure and other harms..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
- Subject:
- Applied Science
- Health, Medicine and Nursing
- Material Type:
- Diagram/Illustration
- Reading
- Provider:
- Research Square
- Provider Set:
- Video Bytes
- Date Added:
- 04/16/2020
